October 25, 2024: Le Journal des biotechs : Hervé Affagard, MaaT Pharma (French only) - MaaT Pharma

To see the interview, click here!

Previous PostNovember 5, 2024: MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
Next PostEvaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club